Non-CID cohort (not diagnosed with RA, PsA, PsO or AS) | All patients: RA, PsO, PsA, or AS cohort | Patients with RA | Patients with PsO and PsA | Patients with PsO but without PsA | Patients with AS | Patients with AS, PsO or PsA | |
---|---|---|---|---|---|---|---|
(N = 1,008,436) | (N = 537,450) | (N = 206,260) | (N = 21,250) | (N = 124,950) | (N = 16,029) | (N = 183,318) | |
Agea, mean ± SD | 46.3 ± 16.3 | 54.0 ± 14.7 | 57.5 ± 13.7 | 51.4 ± 12.2 | 51.1 ± 15.1 | 49.4 ± 13.8 | 51.3 ± 14.4 |
Female, % | 55.1% | 63.1% | 75.8% | 52.8% | 51.5% | 43.8% | 51.3% |
Payment type, % | |||||||
Commercial | 88.9% | 79.3% | 73.6% | 89.0% | 83.6% | 88.3% | 84.9% |
Medicare | 11.1% | 20.7% | 26.4% | 11.0% | 16.4% | 11.7% | 15.1% |
Region of residencea, % | |||||||
South | 39.0% | 37.5% | 39.1% | 40.2% | 36.2% | 36.3% | 36.8% |
North Central | 21.9% | 22.4% | 23.0% | 20.2% | 22.4% | 19.1% | 21.7% |
West | 18.9% | 16.8% | 16.5% | 17.6% | 16.7% | 24.9% | 17.4% |
North East | 18.9% | 22.4% | 20.5% | 21.0% | 24.0% | 18.9% | 23.2% |
Unknown | 1.4% | 0.8% | 0.8% | 1.1% | 0.8% | 0.8% | 0.9% |
Year of index date, % | |||||||
2011 | 30.9% | 24.8% | 28.2% | 23.4% | 26.0% | 25.7% | 25.9% |
2012 | 19.2% | 17.8% | 17.5% | 14.4% | 17.8% | 16.6% | 17.4% |
2013 | 16.8% | 15.8% | 15.1% | 14.6% | 15.6% | 14.8% | 15.4% |
2014 | 13.0% | 13.4% | 12.3% | 13.4% | 13.5% | 12.5% | 13.3% |
2015 | 16.9% | 16.0% | 14.5% | 19.1% | 15.8% | 16.9% | 16.2% |
2016 | 3.3% | 12.2% | 12.4% | 15.1% | 11.3% | 13.5% | 11.9% |
Quan-Charlson Comorbidity Indexb, mean ± SD | 0.5 ± 1.1 | 1.2 ± 1.5 | 1.9 ± 1.4 | 0.9 ± 1.3 | 0.7 ± 1.2 | 0.9 ± 1.3 | 0.7 ± 1.3 |
Extra-articular manifestationsb,c, % | 12.4% | 43.5% | 27.3% | 100.0% | 100.0% | 32.5% | 84.8% |
Gastro-related conditionsb,d, % | 13.6% | 18.8% | 22.1% | 19.5% | 15.3% | 22.5% | 16.7% |
Drug useb, % | |||||||
NSAIDS | 17.0% | 33.3% | 43.7% | 42.5% | 20.5% | 51.5% | 28.3% |
Corticosteroids | 19.5% | 45.3% | 62.3% | 49.3% | 33.4% | 47.7% | 38.2% |
Biologics | 0.1% | 21.0% | 31.9% | 54.3% | 16.4% | 44.9% | 27.0% |
PDE4 inhibitors | 0.0% | 0.4% | 0.1% | 3.2% | 0.9% | 0.1% | 1.2% |
Opioids | 24.0% | 38.8% | 50.0% | 42.3% | 27.6% | 50.0% | 33.1% |
DMARDs | 1.5% | 37.6% | 67.1% | 56.4% | 17.4% | 39.4% | 28.8% |